Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

NCT04890236 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Duvelisib
BIOLOGICAL: Tisagenlecleucel

Sponsor

Emory University

Collaborators

[object Object]
[object Object]
[object Object]